Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Citigroup analyst Joanne Wuensch made the sharpest single move of the day. She cut her target on BSX from $87 to $70 — a 20% reduction — while keeping a Buy rating. That's a notable gap between the bullish call and the revised price target. Boston Scientific carries a $75 billion market cap.
Wuensch also trimmed targets across medtech. PODD fell to $165 from $175. DXCM bucked the trend. Citi raised its target there to $84 from $79, maintaining a Buy on the diabetes device maker.
DLTR had a positive day with analysts. Consensus target prices edged up to $120. The discount retailer saw broad-based target increases as traders watch for a consumer spending resilience story. Short interest sits at 7.4% of free float.
HAS moved the other way. Hasbro's consensus target slipped to $113.53 from $113.80. Analyst sentiment leans heavily sell-side, with 12 sell ratings versus just 0 buys.
CRM saw Citi's Tyler Radke cut his target from $188 to $187 — a marginal move but a downward signal on the CRM giant heading into a busy software earnings season.
A (Agilent Technologies) received the day's only visible upgrade, pushing consensus slightly more bullish.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
